Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Collegium Pharmaceutical Inc shares valued at $332,269 were purchased by Heffernan Michael Thomas on Jul 09 ’25. At $32.17 per share, Heffernan Michael Thomas acquired 10,328 shares.
Also, Heffernan Michael Thomas purchased 790 shares, netting a total of over 24,792 in proceeds.
Before that, Heffernan Michael Thomas had added 14,210 shares to its account. In a trade valued at $444,062, the Former Director bought Collegium Pharmaceutical Inc shares for $31.25 each.
As published in a research note from Needham on January 10, 2025, Collegium Pharmaceutical Inc [COLL] has been rated up from a Hold to a Buy and the price target has been revised to $46. Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late July. As of June 07, 2024, Jefferies has increased its “Hold” rating to a “Buy” for COLL. Earlier on May 10, 2024, Piper Sandler downgraded its rating. Their new recommendation was “a Neutral” for COLL stock which previously was a “an Overweight”.
Analyzing COLL Stock Performance
On last trading session, Collegium Pharmaceutical Inc [NASDAQ: COLL] rose 10.72% to $32.94. The stock’s lowest price that day was $31.4, but it reached a high of $33.45 in the same session. During the last five days, there has been a surge of approximately 10.31%. Over the course of the year, Collegium Pharmaceutical Inc shares have dropped approximately -4.58%.
Is Collegium Pharmaceutical Inc subject to short interest?
Stocks of Collegium Pharmaceutical Inc saw a sharp steep in short interest on 2025-07-15 dropping by -0.61 million shares to 4.21 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 4.82 million shares. A decline of -14.44% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 13.54 of the overall float, the days-to-cover ratio (short ratio) decline to 13.54.
Which companies own the most shares of Collegium Pharmaceutical Inc (COLL)?
In terms of Collegium Pharmaceutical Inc share price expectations, FactSet research, analysts set an average price target of 38 in the next 12 months, up nearly 27.73% from the previous closing price of $29.75. Analysts anticipate Collegium Pharmaceutical Inc stock to reach 50 by 2025, with the lowest price target being 35. In spite of this, 4 analysts ranked Collegium Pharmaceutical Inc stock as Buy at the end of 2025.
